PL163999B1 - Sposób wytwarzania trwalej, krystalicznej, rozpuszczalnej w wodzie soli 2’,3’-dideoksy- 2’,3’- didehydrotymidyny, 2’,3’-dideoksylnozyny lub 2’,3’-dldeoksy-2’-fluoroinozyny PL - Google Patents
Sposób wytwarzania trwalej, krystalicznej, rozpuszczalnej w wodzie soli 2’,3’-dideoksy- 2’,3’- didehydrotymidyny, 2’,3’-dideoksylnozyny lub 2’,3’-dldeoksy-2’-fluoroinozyny PLInfo
- Publication number
- PL163999B1 PL163999B1 PL28517590A PL28517590A PL163999B1 PL 163999 B1 PL163999 B1 PL 163999B1 PL 28517590 A PL28517590 A PL 28517590A PL 28517590 A PL28517590 A PL 28517590A PL 163999 B1 PL163999 B1 PL 163999B1
- Authority
- PL
- Poland
- Prior art keywords
- dideoxy
- formula
- didehydrothymidine
- fluoroinosine
- virus
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 12
- SLWSQPYUSBXANQ-BAJZRUMYSA-N 9-[(2r,3r,5s)-3-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O1[C@H](CO)C[C@@H](F)[C@@H]1N1C(NC=NC2=O)=C2N=C1 SLWSQPYUSBXANQ-BAJZRUMYSA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims abstract description 10
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 5
- 239000011777 magnesium Chemical group 0.000 claims abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000001768 cations Chemical class 0.000 claims abstract description 3
- 229910052749 magnesium Chemical group 0.000 claims abstract description 3
- 239000011591 potassium Chemical group 0.000 claims abstract description 3
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 3
- 239000003125 aqueous solvent Substances 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 159000000000 sodium salts Chemical class 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- -1 2 '3'-dideoxyinosine monohydrate Chemical class 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000002083 X-ray spectrum Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- JQZCHLQWQQFUGR-UOERWJHTSA-N 9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;sodium Chemical compound [Na].O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 JQZCHLQWQQFUGR-UOERWJHTSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35206589A | 1989-05-15 | 1989-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL285175A1 PL285175A1 (en) | 1991-01-14 |
| PL163999B1 true PL163999B1 (pl) | 1994-06-30 |
Family
ID=23383649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL28517590A PL163999B1 (pl) | 1989-05-15 | 1990-05-14 | Sposób wytwarzania trwalej, krystalicznej, rozpuszczalnej w wodzie soli 2’,3’-dideoksy- 2’,3’- didehydrotymidyny, 2’,3’-dideoksylnozyny lub 2’,3’-dldeoksy-2’-fluoroinozyny PL |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JP2926257B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2016765C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ9602347A3 (cg-RX-API-DMAC7.html) |
| DD (1) | DD298406A5 (cg-RX-API-DMAC7.html) |
| MY (1) | MY116824A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ233646A (cg-RX-API-DMAC7.html) |
| PL (1) | PL163999B1 (cg-RX-API-DMAC7.html) |
| SK (2) | SK279130B6 (cg-RX-API-DMAC7.html) |
| TW (1) | TW233301B (cg-RX-API-DMAC7.html) |
| YU (1) | YU92890A (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA903662B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| JP4731121B2 (ja) * | 2004-02-02 | 2011-07-20 | 協和発酵キリン株式会社 | キサンチン誘導体水和物 |
| WO2009119785A1 (ja) * | 2008-03-28 | 2009-10-01 | 浜理薬品工業株式会社 | エチニルチミジン化合物の精製方法 |
| JP5485140B2 (ja) * | 2008-04-10 | 2014-05-07 | 浜理薬品工業株式会社 | ５−メチルウリジンを出発原料とするエチニルチミジン化合物の製造方法 |
-
1990
- 1990-05-11 NZ NZ23364690A patent/NZ233646A/xx unknown
- 1990-05-11 YU YU92890A patent/YU92890A/sh unknown
- 1990-05-12 TW TW79103864A patent/TW233301B/zh active
- 1990-05-14 CA CA002016765A patent/CA2016765C/en not_active Expired - Fee Related
- 1990-05-14 ZA ZA903662A patent/ZA903662B/xx unknown
- 1990-05-14 MY MYPI90000768A patent/MY116824A/en unknown
- 1990-05-14 PL PL28517590A patent/PL163999B1/pl not_active IP Right Cessation
- 1990-05-15 SK SK2372-90A patent/SK279130B6/sk unknown
- 1990-05-15 JP JP12326390A patent/JP2926257B2/ja not_active Expired - Lifetime
- 1990-05-15 DD DD90340679A patent/DD298406A5/de unknown
-
1996
- 1996-08-08 CZ CZ19962347A patent/CZ9602347A3/cs not_active IP Right Cessation
-
1997
- 1997-09-19 SK SK1273-97A patent/SK279253B6/sk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2926257B2 (ja) | 1999-07-28 |
| CA2016765A1 (en) | 1990-11-15 |
| CA2016765C (en) | 1997-10-21 |
| SK127397A3 (en) | 1998-08-05 |
| TW233301B (cg-RX-API-DMAC7.html) | 1994-11-01 |
| PL285175A1 (en) | 1991-01-14 |
| NZ233646A (en) | 1991-10-25 |
| YU92890A (sh) | 1992-09-07 |
| CZ288463B6 (en) | 2001-06-13 |
| SK279253B6 (sk) | 1998-08-05 |
| JPH035477A (ja) | 1991-01-11 |
| DD298406A5 (de) | 1992-02-20 |
| CZ9602347A3 (en) | 2001-06-13 |
| SK237290A3 (en) | 1998-07-08 |
| SK279130B6 (sk) | 1998-07-08 |
| MY116824A (en) | 2004-04-30 |
| ZA903662B (en) | 1991-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI87783B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider | |
| US9351970B2 (en) | Anti-viral pyrimidine nucleoside analogues | |
| CA2623522C (en) | Modified 4'-nucleosides as antiviral agents | |
| EP0576230B1 (en) | 2'-deoxy-2', 2'-difluoro(4-substituted pyrimidine) nucleosides having antiviral and anti-cancer activity and intermediates | |
| PL167097B1 (pl) | Sposób wytwarzania nowych enancjomerycznych analogów nukleozydów purynowych PL PL | |
| US20030176370A1 (en) | Anti-viral pyrimidine nucleoside analogues | |
| JPS63297381A (ja) | ９−〔２−（ヒドロキシメチル）シクロアルキルメチル〕グアニン類 | |
| EP0317128B1 (en) | Anti-HIV Pyrimidine Nucleosides | |
| CZ123293A3 (en) | 2'-deoxy-2',2'-difluoro-(2,6,8-substituted)purinenucleoside derivative, pharmaceutical preparation containing thereof and an intermediate for its preparation | |
| PL163999B1 (pl) | Sposób wytwarzania trwalej, krystalicznej, rozpuszczalnej w wodzie soli 2’,3’-dideoksy- 2’,3’- didehydrotymidyny, 2’,3’-dideoksylnozyny lub 2’,3’-dldeoksy-2’-fluoroinozyny PL | |
| EP0361831A1 (en) | Antiviral nucleoside combination | |
| EP0356166A2 (en) | Therapeutic nucleosides | |
| US7148223B2 (en) | 4′-thio-L-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof | |
| WO1995001355A1 (en) | 9-deazahypoxanthines as pnp inhibitors | |
| EP0398230B1 (en) | Antiviral, highly water soluble, stable, crystalline salts of 2',3'-dideoxyinoside monohydrate, 2',3'-dideoxy-2',3'-didehydrothymidine monohydrate and 2',3'-dideoxy-2'-fluoroinosine hemihydrate | |
| US6207650B1 (en) | Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine | |
| EP0479822B1 (en) | Therapeutic nucleosides | |
| RU2073007C1 (ru) | Способ получения устойчивой водорастворимой кристаллической соли 2,3-дидеоксиинозина | |
| CA1336821C (en) | Therapeutic nucleosides | |
| CZ237290A3 (cs) | Ve vodě vysoce rozpustné, stabilní krystalické soli 2`,3`-dideoxyinosinu, 2`,3`-dideoxy-2`,3`-didehydrothymidinu a 2`,3`-dideoxy-2`-fluorinosinu | |
| JPH06263756A (ja) | イソヌクレオシド誘導体 | |
| WO1991012260A1 (en) | 6-halo- and 2-amino-6-halo-purine 2',3'-dideoxy nucleosides and their use as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20080514 |